ESR1 and breast cancer: This discrepancy could be the result of the activation of other ER-independent estrogen-related signaling pathways in these breast cancer cells, such as insulin-like growth factor 1 (IGF-1)- or vascular endothelial growth factor (VEGF)-mediated signaling cascades [9, 10].